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The fetus and young infant have a high suscep-
tibility to infections with intracellular patho-
gens, suggesting that T cell–mediated immune 
responses are different in early life. A number 
of viruses, including human CMV, herpes sim-
plex type 2, respiratory syncytial virus, and 
HIV, cause more severe or rapidly progressive 
disease in early life as compared with later life 
(Stagno, 2001; Marchant and Goldman, 2005). 
It is generally accepted that this increased sus-
ceptibility to viral infections is related to the 
immaturity of the neonatal immune system. 
This includes intrinsic defects of conventional 
T cells, especially CD4  T cells, and im-
paired DC responses (Lewis and Wilson, 2001; 
White et al., 2002; Maródi, 2006; Levy, 2007; 
Lee et al., 2008). CMV is the most common 
cause of congenital infection, affecting 0.2% of 
all live births in industrialized countries and up 
to 3% in developing countries (Stagno, 2001). 
Although CMV infection causes no detectable 
symptoms in immunocompetent adults, 20% 
of newborns with congenital infection develop 
serious symptoms, including cerebral malforma-
tions, multiple organ failure, deafness, and mental 
retardation (Stagno, 2001; Dollard et al., 2007).
 T cells are T cells expressing  and  
chains as a TCR on their cell surface instead of 
 and  chains as in conventional CD4 and 
CD8  T cells. Together with  T cells, 
they  have  been  conserved  for  >450  million 
years of evolution (Hayday, 2000).  T cells 
are the prototype of unconventional T cells; 
they can react rapidly upon activation and 
show MHC-unrestricted activity (Hayday, 2000; 
Holtmeier and Kabelitz, 2005). Thus, they are 
not influenced by MHC down-regulation strat-
egies used by viruses such as CMV to escape 
conventional T cells (Wilkinson et al., 2008). 
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The fetus and infant are highly susceptible to viral infections. Several viruses, including 
human cytomegalovirus (CMV), cause more severe disease in early life compared with later 
life. It is generally accepted that this is a result of the immaturity of the immune system. 
 T cells are unconventional T cells that can react rapidly upon activation and show major 
histocompatibility complex–unrestricted activity. We show that upon CMV infection in 
utero, fetal  T cells expand and become differentiated. The expansion was restricted to 
V9-negative  T cells, irrespective of their V chain expression. Differentiated  T cells 
expressed high levels of IFN-, transcription factors T-bet and eomes, natural killer  
receptors, and cytotoxic mediators. CMV infection induced a striking enrichment of a 
public V8V1-TCR, containing the germline-encoded complementary-determining- 
region-3 (CDR3) 1–CALGELGDDKLIF/CDR38–CATWDTTGWFKIF. Public V8V1-TCR–
expressing cell clones produced IFN- upon coincubation with CMV-infected target cells  
in a TCR/CD3-dependent manner and showed antiviral activity. Differentiated  T cells 
and public V8V1-TCR were detected as early as after 21 wk of gestation. Our results 
indicate that functional fetal  T cell responses can be generated during development in 
utero and suggest that this T cell subset could participate in antiviral defense in early life.
© 2010 Vermijlen et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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correlated with a higher percentage of  T cells express-
ing the proliferation marker Ki-67 in CMV-infected new-
borns (Fig. 1 C).
The expansion of  T cells in CMV-infected newborns  
is restricted to V9 cells, irrespective of the usage  
of the V chain
To further define specific subsets of  T cells in cord blood 
of CMV-infected newborns, flow cytometry analysis was per-
formed with antibodies specific against V9, V1, V2, and 
V3. In combination with the pan- TCR antibody, the 
V9 antibody can make distinction between V9+ and V9 
Studies in several species have shown an important role for  
T cells in protection against infection, in tumor surveillance, in 
immunoregulation, and in tissue repair (Hayday, 2000; Wang 
et al., 2001; Holtmeier and Kabelitz, 2005; Pennington et al., 
2005; Toulon et al., 2009). In general, they show a rapid and 
robust response before the development of the adaptive im-
munity mediated by conventional T cells. In comparison with 
 T cells,  T cells are not abundant in the peripheral blood 
but  are  highly  enriched  in  tissues  like  the  gut  epithelium 
(Hayday, 2000; Holtmeier and Kabelitz, 2005). The majority 
of  T cells in human adult peripheral blood use the TCR 
V region pair V9V2 (note that according to an alternative 
nomenclature the V9 chain is also termed V2 [Holtmeier 
and Kabelitz, 2005]). This subset has been shown to react 
specifically toward nonpeptide low molecular weight phos-
phorylated metabolites (so-called phosphoantigens) and has 
been the subject of several clinical trials (Wilhelm et al., 2003; 
Dieli et al., 2007; Kabelitz et al., 2007).
Probably in all species,  T cells are the first T cells to 
develop (Hayday, 2000). In contrast to adult peripheral blood 
 T cells, human neonatal cord blood  T cells express di-
verse V and V chains paired in a variety of combinations 
(Morita et al., 1994). Thus the adult-like V9V2 subpopu-
lation only represents a small fraction of the neonatal   
T cells (Parker et al., 1990; Morita et al., 1994; Cairo et al., 
2008). Further illustrating the differences between adult and 
neonatal  T cells, is the demonstration that in vitro expo-
sure toward the same pathogen (Escherichia coli or Pseudomonas 
aeruginosa) results in expansion of V2+  T cells in adult 
peripheral blood but of V1+  T cells in cord blood (Kersten 
et al., 1996). In mice,  T cells are important for the protec-
tion against an intestinal parasite infection in early life but not 
in adult life (Ramsburg et al., 2003), and during human T cell 
ontogeny  T cells mature before  T cells (De Rosa et al., 
2004). However, so far it is not known whether pathogens in 
early life can activate human  T cells. To gain insight into 
the ability of  T cells to mount responses to viruses during 
fetal life, we studied the changes occurring in the  T cell 
compartment during congenital CMV infection.
RESULTS
CMV infection in utero induces expansion of fetal  
 T cells in newborns
To address whether human fetal  T cells are responsive to 
CMV infection in utero, we first compared the percentage of 
 T cells among all T cells in cord blood samples derived 
from 19 CMV-infected newborns versus 22 control CMV-
uninfected  newborns.  In  CMV-infected  newborns,  the   
percentage of  T cells was significantly higher than in 
CMV-uninfected newborns (Fig. 1 A). To exclude the pos-
sibility that this higher percentage of  T cells was the result 
of a decreased number of  T cells, we determined the   
absolute number of  T cells per microliter of blood. In-
deed, significantly more  T cells were present per micro-
liter of cord blood in CMV-infected newborns in comparison 
with controls (Fig. 1 B). The higher number of  T cells 
Figure 1.  CMV infection in utero induces an expansion of   
T cells in newborns. (A) Percentage of  T cells of total T cells (CMV+,  
n = 19; CMV, n = 22). (B) Absolute number of  T cells per microliter of 
cord blood (CMV+, n = 13; CMV, n = 15). (C) Percentage of  T cells 
which are Ki-67+ (CMV+, n = 9; CMV, n = 15) in CMV-infected (gray 
boxes) and CMV-uninfected (white boxes) newborns. In box-and-whisker 
graphs, the line at the middle is the median, the box extends from the 
25th to 75th percentile, and the error bars, or whiskers, extend down to 
the lowest value and up to the highest.JEM VOL. 207, April 12, 2010 
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cells negative for V9, including V9V1+, V9V2+, and 
V9V3+  T cells in CMV-infected newborns compared 
with uninfected newborns (Fig. 2, A and B). On a selected 
number of CMV-uninfected and CMV-infected newborns, 
we performed a more detailed analysis of the  chain usage. 
In CMV-uninfected newborns, there was a slight preference for 
V4 and V9, whereas upon CMV infection the VI family 
members V4 and V8 were highly expanded (Fig. S1).
 T cells (Fig. 2 A). V9 is the only member of the VII 
family; thus the V9 cells express V chains of the VI fam-
ily (Hayday, 2000). The combination of V1, V2, and V3 
antibodies  stained  the  vast  majority  (90%;  unpublished 
data) of the cord blood  T cells. This approach allows us 
to  identify  six    T  cell  subpopulations  in  cord  blood: 
V9+V1+, V9V1+, V9+V2+, V9V2+, V9+V3+, 
and V9V3+. We detected higher percentages of  T 
Figure 2.  The expansion of  T cells in CMV-infected newborns is restricted to V9  T cells, irrespective of the usage of the  
V chain. (A) Expression of V9 versus V1, V2, or V3 by  T cells from CMV-infected newborn Pos13 (top) and CMV-uninfected newborn Neg4 (bottom). 
Numbers in dot plots are the percentages of total T cells. (B) Box-and-whisker graph (defined as in Fig. 1) of the percentages of V9+V1+, V9+V2+, 
V9+V3+, V9V1+, V9V2+, and V9V3+  T cell subpopulations of  T cells expressed as a percentage of total T cells. CMV+, n = 10–18;  
CMV, n = 14–22.810 Antiviral  T cells in utero | Vermijlen et al.
NKRs. Expression of a range of NKR genes was increased in 
 T cells from CMV-infected newborns in comparison with 
 T cells from CMV-uninfected newborns (Fig. 3, KIR2DL1; 
Table S1). This included both activating and inhibitory re-
ceptors (Table S1) and involved all the NKR families: the 
killer immunoglobulin receptor (KIR) family, the C-type lec-
tin family (CD94/NKG2A/NKG2C), and the natural cyto-
toxicity receptor (NCR) family (NKp46; Lanier, 2008). In 
CMV-uninfected newborns, there were either no or very few 
 T cells (CD94/NKG2A/NKG2C, CD158a/h [KIR2DL1/
KIR2DS1], and CD158b/j [KIR2DL2/KIR2DS2]) or a   
significant fraction of  T cells (NKG2D and KLRG1) ex-
pressing NKR on their membrane, as determined by flow   
cytometry (Table I). In CMV-infected newborns, signifi-
cantly more  T cells expressed all these NKRs (Table I).
Cytotoxic mediators. In general, cytotoxic lymphocytes can 
kill target cells by two main mechanisms: exocytosis of granule-
associated molecules, such as granzymes, perforin, and gra-
nulysin,  or  binding  to  receptors  with  ligands  of  the  TNF 
superfamily  (e.g.,  FasL  and  TRAIL).  Among  the  >47,000 
transcripts analyzed, the two genes displaying the most in-
creased expression upon CMV infection were members of the 
granzyme family: granzyme B and granzyme H (Fig. 3). In 
addition, other granzyme family members (granzyme A and 
granzyme M), perforin, granulysin, FasL, and TRAIL were 
increased (Table S1). In CMV-uninfected newborns, there 
was either no or only a low percentage of  T cells express-
ing perforin and granzyme A, as demonstrated by flow cytom-
etry (Table I). In CMV-infected newborns, the percentages of 
 T cells expressing perforin or granzyme A were highly   
increased (Table I). This expression was clearly associated with 
the late differentiation status of the  T cells (Fig. S2 A).
Chemokines and chemokine receptors. The genes for the 
chemokines CCL3 (MIP-1), CCL4 (MIP-1), and CCL5 
 T cells from CMV-infected newborns are activated  
and differentiated
Next, we evaluated whether the expansion of fetal  T cells 
after congenital CMV infection was accompanied by activa-
tion and/or differentiation of these cells. A significant pro-
portion of  T cells from CMV-infected newborns expressed 
the activation marker HLA-DR, whereas expression was   
virtually absent in uninfected controls (Table I). Down- 
regulation of CD27 and CD28 expression has been shown to 
be associated with advanced or late differentiation in CD8 
 T cells upon CMV infection (Appay et al., 2002; Marchant 
et al., 2003; van Leeuwen et al., 2006). These markers 
have also been used to identify differentiated human   
T cells (Morita et al., 2007). Although CD27CD28   
T cells were absent from CMV-uninfected newborns, a large 
proportion of  T cells showed this phenotype in CMV- 
infected newborns (Table I). This differentiation was most 
pronounced in the V9  T cell subpopulation (unpub-
lished  data).  Collectively,  these  data  clearly  show  that 
upon congenital CMV infection,  T cells are activated, 
undergo cell division, and become differentiated.
Expression of NK receptors (NKRs), cytotoxic mediators,  
and IFN- is highly increased in  T cells  
of CMV-infected newborns
To gain insight into the function of fetal  T cells in new-
borns  with  congenital  CMV  infection,  we  compared  the 
gene expression profiles of  T cells derived from three 
CMV-infected newborns versus three CMV-uninfected new-
borns. 1,622 genes were increased and 654 decreased upon 
infection (using the selection criteria described in Materials 
and methods; M > 0.05, P < 0.05). More than 100 genes as-
sociated with cell cycle showed increased expression upon 
CMV infection (as analyzed with DAVID; not depicted), 
coinciding with the expansion data (Fig. 1).
Table I.  Percentage of activation (HLA-DR) and differentiation (CD27, CD28) markers, NKRs (CD94, NKG2A, NKG2C, CD158, 
NKG2D, and KLRG1), cytotoxic mediators (perforin and granzyme A), and chemokine receptor CX3CR1 on  T cells derived from 
CMV-infected and CMV-uninfected newborns
Marker CMV+ CMV p (CMV+ versus CMV)
HLA-DR+ 6.34 (2.87–10.68) 0.58 (0.27-0.80) <0.0001
CD27CD28 43.82 (31.97–48.98) 0.22 (0.13-0.45) <0.0001
CD94+ 33.21 (23.68–57.20) 4.44 (3.61-5.56) <0.0001
NKG2A+ 10.99 (4.27–20.64) 3.84 (2.33-5.11) 0.0464
NKG2C+ 28.00 (10.77–35.54) 1.17 (0.91–3.68) <0.0001
CD158a/h+ 14.70 (6.61–30.53) 1.56 (0.94–3.34) <0.0001
CD158b/j+ 46.60 (29.07–51.38) 2.75 (2.56–3.32) <0.0001
NKG2D+ 69.18 (64.42–76.76) 52.38 (46.26–63.08) 0.0001
KLRG1+ 38.85 (27.80–45.41) 24.70 (16.73–28.72) 0.0009
perforin+ 61.50 (51.97–73.32) 0.67 (0.48–1.77) <0.0001
granzyme A+ 69.82 (57.97–79.63) 4.38 (2.82–6.28) <0.0001
CX3CR1+ 43.21 (25.08–57.96) 1.11 (0.65–2.10) 0.0003
Data for CMV+ and CMV represent median (25–75% percentile). The gate is put on CD3++. CMV+, n = 8–18; CMV, n = 9–22.JEM VOL. 207, April 12, 2010 
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measured by the mean fluorescence intensity (MFI), was 
consistently much higher in CD27CD28  T cells than 
in CD27+CD28+  T cells (median within CD27CD28 
  T  cells,  318  MFI;  median  within  CD27+CD28+    
T cells, 102 MFI; P = 0.0023). Upon a brief polyclonal stim-
ulation in vitro, the majority of CD27CD28 differentiated 
  T  cells  of  CMV-infected  newborns  produced  IFN-  
(Fig. 4 B), whereas the CD27+CD28+  T cells produced 
significantly less IFN- (median within CD27CD28   
T cells, 68%; median within CD27+CD28+  T cells, 22%; 
P = 0.0006). T-bet and IFN- expression within  T cells 
from CMV-uninfected newborns were similar to the expres-
sion found within CD27+CD28+  T cells from CMV- 
infected newborns (unpublished data).
The CDR31 and CDR32 are highly restricted  
upon congenital CMV infection
To study the impact of CMV infection during fetal life on 
the TCR repertoire of  T cells, we assessed the degree of 
junctional  diversity  of  the  complementary-determining- 
region-3 (CDR3) of the V1 (CDR31) and V2 (CDR32) 
chains by spectratyping on 11 CMV-uninfected and 13 
CMV-infected cord blood samples. CMV-uninfected cord 
blood samples showed polyclonal profiles for both CDR31 
(as described previously; Beldjord et al., 1993) and CDR32. 
In contrast, the CDR31 and CDR32 repertoires became 
highly  restricted  in  the  vast  majority  of  CMV-infected   
newborns (Fig. 5 A and Fig. S3). To quantify this restriction, 
we calculated an index of oligoclonality for CDR31 and 
CDR32 as described previously (Déchanet et al., 1999; Pitard 
et al., 2008). For both CDR3s, the index of oligoclonality 
(RANTES), all ligands for CCR5, and two chemokine re-
ceptor  genes  (CCR5  and  CX3CR1)  showed  increased   
expression in  T cells from CMV-infected newborns in 
comparison with  T cells from CMV-uninfected newborns 
(Table  S1).  CCR7  gene  expression  was  decreased  upon 
CMV infection (M = 2.27, A = 8.07, P = 0.03). In CMV-
uninfected newborns, there were no or only a low percent-
age of  T cells expressing CX3CR1 (fractalkine receptor) 
on their membrane, as determined by flow cytometry (Table I). 
In CMV-infected newborns, the percentage of  T cells   
expressing CX3CR1 was highly increased (Table I), which 
was clearly associated with the late differentiation phenotype 
of the  T cells (Fig. S2 B).
Cytokines. Only a limited number of cytokine genes showed 
increased expression in  T cells derived from CMV- 
infected newborns in comparison with  T cells derived 
from CMV-uninfected newborns (Table S1). IFN- was one 
of the most increased expressed genes (Fig. 3 and Table S1). 
Strikingly, gene expression of transcription factors known to 
be implicated in IFN- production, namely T-bet (M = 2.37, 
A = 6.64, P = 0.000112) and eomes (M = 3.02, A = 6.31,   
P = 0.000246), was highly increased. The high expression of 
T-bet was confirmed at protein level by flow cytometry in 
 T cells from CMV-infected newborns and was associated 
with the differentiation status of  T cells (Fig. 4 A).   
Almost all CD27CD28  T cells expressed T-bet, whereas 
CD27+CD28+  T cells expressed significantly lower levels 
of this transcription factor (median within CD27CD28  
T cells, 97%; median within CD27+CD28+  T cells, 28%; 
P = 0.0006). In addition, T-bet expression per cell, as   
Figure 3.  Gene expression analysis of  T cells derived from three CMV-infected newborns versus  T cells derived from three  
CMV-uninfected newborns. MA plot of differentially expressed genes in  T cells upon CMV infection. M (log2 of fold change) reflects the differential  
expression of a gene. Positive and negative values indicate genes which are up- and down-regulated, respectively, upon CMV infection. A (mean expres-
sion) reflects the overall expression level of a gene. Each dot represents one gene. Examples of highly expressed NKR (KIR2DL1), cytotoxic mediators 
(granzyme B, granzyme H, perforin, and granulysin), cytokines (IFN-), and chemokines (CCL4) are indicated.812 Antiviral  T cells in utero | Vermijlen et al.
the c of the joining gene 1 (J1) or completely formed by 
the gat of the D3 (Table S2, dark gray). Besides ELGDD   
itself, few longer variants were present in some CMV-infected 
newborns, which were enriched as well, containing one (Pos3) 
or two (Pos3 and Pos11) extra Ts after the first D of ELGDD 
(Table S2). In contrast to the other CDR31 sequences, the 
highly enriched ELGDD sequence did not contain P/N addi-
tions and was thus completely germline encoded (Table S2).
In  comparison  with  CDR31,  the  degree  of  shared 
CDR32  sequences  among  the  CMV-infected  newborns 
was much less clear (Table S3). Among eight CMV-infected 
newborns, three exhibited enrichment of the same CDR32 
sequence (Pos8, Pos9, and Pos10; Table S3). No other 
obvious similarities were found between different enriched 
CDR32 sequences of different CMV-infected newborns. 
V1 almost always paired with J1, whereas V2 had a pref-
erence  for  J3  (Table  S2  and  Table  S3).  Sequencing  of 
CDR31 and CDR32 of CMV-uninfected newborns con-
firmed the polyclonal repertoire as found by spectratyping 
(Table S2 and Table S3).
We wondered whether the V1 chain, containing the 
public CDR31, from CMV-infected newborns cells had a 
preference for pairing with specific V chains. By costaining 
of V1 and V2/3/4, V5/3, V8, or V9, we determined 
that within CMV-uninfected newborns V1 had a preference 
was significantly higher in CMV-infected newborns than in 
CMV-uninfected newborns (Fig. 5 B). Moreover, the re-
striction  of  CDR31  of  CMV-infected  newborns  was   
enriched for the same length (11 aa) in all CMV-positive 
newborns (Fig. 5 A, arrows). This length was either absent or 
minimally present in CMV-uninfected newborns (Fig. 5 A). 
In contrast to CDR31, the length of the enriched CDR32 
sequences in CMV-infected newborns varied from newborn 
to newborn (Fig. S3). It is of note that CMV-infected new-
born Pos10 showed a polyclonal CDR31 repertoire corre-
sponding with the absence of CD27CD28 differentiated 
V1+  T cells (Fig. 5 A). In contrast, V2+  T cells of this 
newborn were well differentiated, corresponding to a re-
stricted CDR32 repertoire (Fig. S3).
Public germline-encoded CDR31 and CDR38 sequences 
are highly enriched in CMV-infected newborns
Because the CDR31 of CMV-infected newborns was highly 
enriched at 11 aa, we wondered whether this region included 
the same or similar sequences. Strikingly, at amino acid level 
in all 12 sequenced CMV-infected newborns the CDR31 
of 11 aa had exactly the same sequence: CALGELGDDKLIF, 
or ELGDD for short (Table S2; Fig. 5 A). At the nucleotide 
level, two variants were observed: the first D of ELGDD was 
either formed by the ga of the diversity gene 3 (D3) and 
Figure 4.  Differentiated (CD27CD28)  T cells from CMV-infected newborns express highly the transcription factor T-bet and produce 
high levels of IFN-. Flow cytometry plots for T-bet (A) and IFN- (B), gated on CD27CD28 versus gated on CD27+CD28+  T cells of a CMV-positive 
newborn (Pos12), representative of seven CMV-infected newborns. Cells were stimulated for 4 h with PMA/ionomycin before intracellular staining for 
IFN-. Unstimulated cells showed no IFN- staining.JEM VOL. 207, April 12, 2010 
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Figure 5.  The CDR31 and CDR32 repertoire of  T cells from CMV-infected newborns are oligoclonal, and CDR31 is highly enriched 
for a single sequence. (A) Spectratyping plots of the CDR31 of CMV-uninfected and CMV-infected newborns. Each box represents one donor. The num-
bers at the left top of each box represents the percentage of V1+  T cells, expressed as percentage of total T cells. The numbers at the right top of each 
box represent the percentage of CD27CD28 cells of V1+  T cells. The arrows indicate the sequences at CDR31 of 11-aa size of the CMV-infected 
newborns that have been sequenced: CALGELGDDKLIF (Table S2). (B) Index of oligoclonality for CDR31 and CDR32, determined as described in Materials 
and methods. Lines indicate medians.814 Antiviral  T cells in utero | Vermijlen et al.
extra Y after D (Fig. 6 B; Table S4). This sequence was not 
detected in CMV-uninfected newborns (Table S4). As for the 
public CDR31 sequence, the public CDR38 was com-
pletely germline encoded (Table S4).
The public V8V1 TCR reacts against CMV-infected  
target cells
To verify whether the public V8V1 TCR reacts against 
CMV-infected target cells, we generated  T cell clones ex-
pressing the public TCR containing the CDR31-ELGDD 
and  CDR38-DTTGW  from  CMV-infected  newborns 
Pos4 (11 public clones) and Pos6 (21 public clones). All 
clones expressing CDR31-ELGDD coexpressed CDR38-
DTTGW, whereas clones with a different CDR31 expressed 
other CDR3’s (unpublished data), showing in a direct way 
the  preferential  pairing  between  CDR31-ELGDD  and 
CDR38-DTTGW. A brief coincubation (6 h) of public 
for pairing with V2/3/4 (Fig. 6 A), whereas V2 and V3 
had rather a preference for V9 and V5/3, respectively (not 
depicted).  In  contrast,  in  CMV-infected  newborns  with 
highly expanded  T cells, V1 had a clear preference for 
pairing with V8 (Fig. 6 A), whereas V2 and V3 had rather 
a  preference  for  V2/3/4  (not  depicted).  Because  of  this 
preferential pairing of V1 with V8, we performed spec-
tratyping for CDR38 on six CMV-uninfected and six 
CMV-infected newborns. The CDR38 of CMV-uninfected 
newborns showed a polyclonal repertoire. In contrast, the 
CDR38 repertoire became highly restricted in CMV- 
infected newborns, showing a high enrichment at a length of 
11 aa in five out of six CMV-infected newborns. The sixth 
CMV-infected newborn (Pos13) had a high enrichment at   
12 aa (Fig. 6 B). Sequencing revealed that the CDR38   
sequences  at  11  aa  contained  all  the  same  sequence:   
CATWDTTGWFKIF (DTTGW for short). Pos13 had an 
Figure 6.  The V1 chain on  T cells of CMV-infected newborns preferentially pairs with a public V8 chain. (A) The percentage of V1+ 
 T cells positive for V2/3/4, V5/3, V8, or V9 determined in three CMV-infected (Pos4, Pos6, and Pos13) and three CMV-uninfected newborns.  
(B) Spectratyping for CDR38 of six CMV-uninfected newborns (top row) and six CMV-infected newborns (bottom row). The arrow indicates the public 
CDR38 sequence CATWDTTGWFKIF of 11 aa (Table S3). The CDR38 of Pos13 contains 1 aa more (Y).JEM VOL. 207, April 12, 2010 
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negative  and  13  CMV-positive  fetuses).  At  these  earlier 
gestation times, the  T cells were already clearly differenti-
ated  (down-regulation  of  CD27  and  CD28)  and  showed 
high expression of perforin (Fig. 9 A), granzyme A, and NKR 
(not depicted). From four CMV-infected fetuses, we per-
formed spectratyping and sequencing for CDR31 at time of 
delivery and at earlier gestation time (Fig. 9 B). We found 
that the CDR31-ELGDD sequence was already enriched at 
as early as 21 wk of gestation (Fig. 9 B and Table S2). Few 
other CDR31 sequences that were present at early gestation 
time were also present at time of delivery (Table S2, fetus 
Pos4 [14 aa] and fetus Pos13 [17 aa]). As observed at time of 
clones with CMV-infected human embryonic lung fibro-
blasts induced IFN- production, which was blocked by the 
presence of a soluble anti-CD3 antibody (OKT3) showing 
the involvement of the public V8V1 TCR/CD3 complex 
in the recognition of CMV-infected target cells (Fig. 7 
and Fig. S4). Control  T cell clones of CMV-uninfected   
newborns did not show CMV-induced IFN- production. 
To gain insight into the antiviral activity of the  T cell 
clones, we conducted additional experiments. Public clones 
killed infected target cells (Fig. 8 A) and inhibited CMV rep-
lication (between one and two log10 inhibition; Fig. 8 B), 
whereas control V9V2 T clones had no or only a moderate 
effect (Fig. 8).
Differentiation and oligoclonal expansion of fetal  T cells 
can occur early during gestation
To explore the possibility that  T cells could develop a   
response toward CMV infection early during fetal life, we 
analyzed the  T cells from fetal cord blood samples col-
lected between 20 and 29 wk of gestation (from 12 CMV-
Figure 7.   T cell clones expressing the public V8V1 TCR 
display reactivity against CMV-infected cells via TCR/CD3. Clones 
were coincubated for 6 h with human embryonic fibroblasts not in-
fected (white bars) or infected (gray bars) with CMV (TB40/E). During 
coincubation either a control IgG2a antibody (ctrl) or the anti-CD3 anti-
body OKT3 (anti-CD3) was present in soluble form. Results are shown 
for one public clone from CMV-infected newborn Pos4 (V8V1-Pos4) 
and for one public clone of CMV-infected newborn Pos6 (V8V1-Pos6) 
and are representative of five independent experiments involving 11 
different public V8V1 clones.
Figure 8.  Public V8V1 clones kill CMV-infected target cells and 
inhibit CMV replication in vitro. (A) CMV-infected (TB40/E) human 
embryonic fibroblasts were coincubated with either  T cell clones  
expressing the public V8V1 TCR (derived from CMV-infected newborns 
Pos4 and Pos6) or a control V9V2 clone (derived from a CMV- 
uninfected newborn) at the indicated effector to target ratios. After 4 h of 
coincubation, the level of DNA fragmentation in the target cells was 
quantified. Results are representative of three independent experiments. 
(B) Human embryonic fibroblasts were incubated with CMV for 2 h, 
washed, and incubated with medium alone, with a public V8V1 clone 
from CMV-infected newborn Pos6 or with a control V9V2 clone from a 
CMV-uninfected newborn. After 7 d, the quantity of infectious CMV from 
the supernatant was determined by a plaque assay (PFU, plaque forming 
units). Shown are the mean ± SEM of quadruplicate determinations.  
Results are representative of two independent experiments.816 Antiviral  T cells in utero | Vermijlen et al.
infected fetuses and remained present with time. In contrast, 
the enriched sequences of the CDR32 were variable from 
one fetus to the other and changed during gestation time. 
Furthermore, the CDR3 sequence associated with the 
CDR31-ELGDD sequence, namely CDR38-DTTGW, 
was also already enriched at as early as 21 wk of gestation 
delivery,  CDR32  spectratyping  showed  more  variability 
between fetuses (unpublished data). Furthermore, CDR32 
appeared to vary with time within the same fetus (Table S3, 
compare CDR32 sequencing data of Pos4 at 20 wk, 5 d and 
at 40 wk, 0 d of gestation). Thus, the enriched CDR31-
ELGDD sequence appeared early during gestation in CMV-
Figure 9.  Differentiation and oligoclonal (CALGELGDDKLIF) expansion of fetal  T cells can occur early during gestation. (A) Expression of 
CD27/CD28 and perforin by  T cells from a representative CMV-uninfected (bottom) and a representative CMV-infected fetus (Pos4; top), both at the 
gestational age of 20–21 wk. Dot plots are presented and numbers indicate the percentages of  T cells negative for CD27 and CD28 and positive for 
perforin. CMV, results are representative of 12 (CD27CD28) and 7 (perforin) fetuses (gestation range: 20 wk, 3 d–29 wk, 2 d); CMV+, results are represen-
tative of 13 (CD27CD28) and 5 (perforin) fetuses (gestation range: 20 wk, 5 d–29 wk, 2 d). (B) Spectratyping for CDR31 of four CMV-infected fetuses 
for which we had blood samples both at the time of delivery and at earlier gestation times. The enrichment for the CDR31 size of 11 aa consists of the 
sequence CALGELGDDKLIF (Table S2).JEM VOL. 207, April 12, 2010 
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in the microarray analysis: CCR5 and CX3CR1 (fractalkine 
receptor). Fractalkine can be produced by endothelial cells in 
the context of CMV infection (Bolovan-Fritts et al., 2004), 
thus possibly attracting differentiated CX3CR1+ fetal  
T cells to the site of infection. Together, our data indicate 
that fetal  T cells generated in utero during CMV infec-
tion are equipped with a range of antiviral effector mecha-
nisms, including IFN- production and granule-mediated 
cytotoxicity. Indeed,  T cell clones generated from CMV-
infected  newborns  killed  CMV-infected  cells  and  limited 
CMV replication in vitro. It is therefore likely that they par-
ticipate in the limitation of the viral spread in the fetus. In 
kidney-transplanted patients with acute CMV infection, ex-
pansion of  T cells is associated with the clinical resolu-
tion, suggesting a protective role of the expanded  T cells 
(Lafarge et al., 2001; Halary et al., 2005).
We demonstrated that CMV infection during fetal life 
leads to the oligoclonal expansion of  T cells, which is 
characterized by highly restricted CDR31 and CDR32 
repertoires and by the high enrichment of a public CDR31-
CDR38 sequence. Expanded  T cells were negative for 
V9 and included V1+, V2+, and V3+ cells. In contrast, in 
adult CMV-infected kidney transplanted patients, expanded 
 T cells do not include V2+ cells and there is no restric-
tion  of  CDR32  (Déchanet  et  al.,  1999).  V9V2+    
T cells are very rare in the adult (Morita et al., 1994), pro-
viding a possible explanation of why Déchanet et al. (1999) 
did not detect any expansion of this subset in adults (Pitard 
et al., 2008).
TCR- chains have the highest potential diversity in the 
CDR3 loop (1016 combinations) among all antigen recep-
tor chains (TCR-, TCR-, TCR-, TCR-, IgH, and IgL) 
because multiple D gene segments can join together, all D 
gene segments can be read in all three open reading frames, 
and N nucleotides can be inserted into the junctions of each 
of the joining segments (Chien and Konigshofer, 2007). 
Therefore, it was surprising to identify a high enrichment of 
exactly the same CDR31 sequence (i.e., public CDR3) in 
all fetuses with differentiated V1+  T cells upon congeni-
tal CMV infection (ELGDD). It has been suggested that 
much of the diversity of the CDR3 junctions of the  chain 
may confer different affinities of the  TCR rather than the 
ability to recognize different ligands (Chien and Konigshofer, 
2007). In addition, in adult CD8  T cells, public CMV-
reactive TCR sequences bind the MHC–peptide complexes 
with higher affinity than private MHC peptide–specific TCR 
sequences (Trautmann et al., 2005; Day et al., 2007). This 
suggests that the public CDR31-ELGDD is enriched by 
recognition  of  a  CMV-induced  ligand  with  high  affinity. 
Our results show for the first time, to our knowledge, the 
expansion of a public  TCR CDR3 in the context of an 
infection.  Furthermore,  we  demonstrated  that  the  public 
CDR31 pairs with a public CDR38 sequence (DTTGW), 
indicating that both the  and  chain are important for the 
recognition of the putative ligand. In addition, this public 
V8V1 TCR showed reactivity against CMV-infected   
(Table S4; CMV-infected newborn Pos4). Thus, despite the 
recent description of selective impairments of  T cells in 
preterm infants (Gibbons et al., 2009),  T cell are able to 
develop robust responses toward CMV infection in utero at 
as early as 21 wk of gestation.
DISCUSSION
In this study, we demonstrate that CMV infection in utero 
leads to the oligoclonal expansion and differentiation of fetal 
 T cells, which express high levels of NKR and cytotoxic 
mediators and produce IFN-. Both activating (e.g., activating 
KIR, NKG2C, and NKG2D) and inhibitory (e.g., inhibitory 
KIR, NKG2A, and KLRG1) NKRs were highly expressed 
in  T cells derived from congenitally infected newborns. 
This would allow them to sense CMV-induced changes in 
infected target cells; HLA-E (ligand for NKG2A/NKG2C) 
expression is increased upon CMV infection, whereas classi-
cal MHC class I (ligands for KIR) expression is decreased 
(Wilkinson et al., 2008). In comparison with conventional   
T cells, it has been described that adult  T cells express 
high levels of NKR, like members of the C-type lectin and 
the KIR family (Battistini et al., 1997; De Libero, 1999;   
Pennington et al., 2005). We confirmed the expression of 
KLRG1 on  T cells in CMV-uninfected newborns (Eberl 
et al., 2005) and also showed that NKG2D is constitutively 
expressed. In contrast, unlike NK cells (Dalle et al., 2005), 
other  NKRs  (CD94/NKG2x  and  KIR  family  members) 
were not expressed or were expressed at very low levels on 
 T cells from CMV-uninfected newborns. Thus the ma-
jority of NKR expression on adult  T cells is likely to be 
the consequence of infections after birth. CMV infection in 
utero induced the up-regulation of various cytotoxic media-
tors in fetal  T cells, including almost all members of the 
granzyme family, perforin, granulysin, FasL, and TRAIL. 
Perforin and granulysin are membrane-disrupting molecules 
and most granzymes have been shown to be involved in   
killing of target cells, with most evidence for granzyme B 
(Lieberman, 2003; Chowdhury and Lieberman, 2008). In ad-
dition, other granzyme-mediated antiviral mechanisms have 
been recently described: granzyme A plays a proinflamma-
tory role (Metkar et al., 2008), granzyme M targets -tubulin 
(Bovenschen et al., 2008), and granzyme H cleaves La, a 
phosphoprotein involved in cellular and viral RNA metabo-
lism (Romero et al., 2009). It is of note that granzyme   
H cleaves an adenovirus-encoded granzyme B inhibitor   
(Andrade et al., 2007). Analysis of the profile of cytokine 
genes expressed in fetal  T cells derived from CMV-infected 
newborns revealed the restricted high expression of IFN-. 
In parallel, we detected elevated levels of the T-box tran-
scription factors T-bet and eomes, which are involved in 
the rapid and vigorous IFN- production by  T cells (Yin 
et al., 2002; Chen et al., 2007). In contrast, expression of 
other transcription factor genes like GATA3 (Th2) or ROR-t 
(Th17)  was  not  affected,  coinciding  with  the  absence  of 
modulation of cytokine genes associated with these Th sub-
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newborns and 22 uninfected control newborns as well as 13 infected and 12 
uninfected fetuses. Symptomatic congenital infection was diagnosed in fetus 
Pos12 who had brain lesions at antenatal magnetic resonance imaging and an 
abnormal postnatal neurological development and in fetus Pos5 who had an 
abnormal postnatal neurological development.
Flow cytometry. The following antibodies were used: CD3–pacific blue 
(clone  SP34-2),  -PE  (11F2),  -FITC  (11F2),  CD27-APC  (L128), 
CD27-FITC  (L128),  CD94-APC  (HP-3D9),  CD158a-FITC  (HP-3E4), 
CD158b-FITC  (CH-L),  HLA-DR-APC-Cy7  (L243),  NKG2D-APC 
(1D11), perforin-FITC (G9), granzyme A–FITC (CB9), Ki-67–FITC 
(B56),  and  IFN-–FITC  (25723.11;  BD);  V2-FITC  (IMMU389), 
NKG2A-PE  (Z199),  CD3-ECD  (UCHT1),  and  CD28-ECD  (CD28.2; 
Beckman Coulter); V1-FITC (TS1; Thermo Fisher Scientific); NKG2C-
APC (134591; R&D Systems); CX3CR1-PE (2A9-1; MBL International); 
and T-bet–PE (4B10; eBioscience). V5-PC5 (IMMU360) and V3-FITC 
(P11.5B) were derived from Beckman Coulter via custom design service. 
V2/3/4-biotin and V2/3/4-FITC (23D12), V4-FITC, V5/3-biotin 
(56.3), and V8-biotin (R4.5.1) were provided by D. Wesch (Institute of 
Immunology, University of Kiel, Kiel, Germany; Kabelitz et al., 1994; Hinz 
et al., 1997; Wesch et al., 1998). KLRG1–Alexa Fluor 488 (13F12F2) was 
provided  by  H.  Pircher  (University  of  Freiburg,  Freiburg,  Germany;   
Marcolino et al., 2004) and unlabeled V3 antibody by E. Scotet (Institut 
National de la Santé et de la Recherche Médicale U601, Nantes, France; 
Peyrat et al., 1995). Staining was done on whole blood. Red blood cells were 
lysed  using  FACS  Lysing  solution  (BD).  The  absolute  number  of    
T cells in whole blood was determined using Trucount beads (BD). Intracel-
lular staining for perforin-FITC, granzyme A–FITC, and Ki-67–FITC was 
performed with the Perm 2 kit (BD) and for T-bet–PE with the Foxp3   
staining buffer set (eBioscience). For the detection of IFN-, PBMCs were 
stimulated for 4 h with 10 ng/ml PMA and 2 µM ionomycin in the presence 
of 2 µM monensin. Staining was done using the Cytofix/Cytoperm kit (BD). 
Cells were run on the CyAn flow cytometer equipped with three lasers (405, 
488, and 633 nm) and data were analyzed using Summit 4.3 (Dako).
Microarray analysis. PBMCs were isolated from cord blood by Lympho-
prep gradient centrifugation (Axis-Shield). After depletion of remaining red 
blood  cells  and  CD4+  cells  by  magnetic  cell  sorting  (Miltenyi  Biotec), 
CD3++ lymphocytes were sorted till high purity (>99%) with a MoFlo 
sorter (Dako). The  T cell yield varied from 80,000–300,000 cells per cord 
blood  sample.  Total  RNA  was  isolated  using  the  RNeasy  Micro  kit   
(QIAGEN) from sorted  T cells derived from three CMV-infected   
newborns and three CMV-uninfected newborns. RNA concentration was 
measured using the NanoDrop (Thermo Fisher Scientific) and RNA quality 
was assessed using the Bioanalyzer 2100 (Agilent Technologies). RNA was 
amplified into biotin-labeled complementary RNA (cRNA) by one-round 
in vitro transcription using the Premier kit (Applied Biosystems). The cRNA 
was fragmented and hybridized on the Human Genome U133 Plus 2.0 
GeneChip (Affymetrix). Staining and scanning was done on the Affymetrix 
platform. The procedures, from RNA quality control to generation of raw 
data (CEL files), were performed at DNAVision (Gosselies, Belgium). The 
raw data were analyzed using the Affy package of Limma (linear models for 
microarray data; www.bioconductor.org), including fitting a linear model 
(lmfit) as described previously (Vermijlen et al., 2007). M- and A-values for 
each gene were generated. M (log2 of the fold change) is related to the de-
gree of differential expression between the  T cells from CMV-infected 
newborns versus  T cells from CMV-uninfected newborns, whereas A is 
a measurement of the mean signal intensity. Genes were regarded as differ-
entially expressed if the absolute M-value was >0.5 with a p-value <0.05. 
Genes with M-values >0.5 are enriched in the  T cells derived from 
CMV-infected newborns, whereas genes with M-values <0.5 are enriched 
in the  T cells derived from CMV-uninfected newborns. The Database 
for Annotation, Visualization and Integrated Discovery (DAVID; http:// 
david.abcc.ncifcrf.gov/) was used to assist in the discovery of functionally 
related groups of differentially expressed genes. Microarray data and procedures 
target cells in vitro. It is of note that both the CDR31- 
ELGDD and CDR38-DTTGW were germline encoded, as 
the CDR31 was only formed by the V1 gene, one D 
gene (D3) and the J1 gene, and the CDR38 by the V8 
gene and the JP1 gene, without any addition of P/N nucle-
otides. Similarly, the mouse T22/T10-binding CDR3 does 
not contain N nucleotides (Adams et al., 2005; Chien and 
Konigshofer, 2007). This contrasts highly with  T cells, 
where  the  most  critical  amino  acids  in  the  CDR3  and 
CDR3 involved in the recognition of the MHC–peptide 
complex are encoded either completely or partially by N nu-
cleotides (Davis et al., 1998; Chien and Konigshofer, 2007).
Despite the immaturity of the neonatal immune system 
and possible mechanisms of immunosuppression by regula-
tory T cells (Mold et al., 2008), CMV infection is efficient in 
stimulating vigorous responses of both  T cells and CD8 
 T cells (Marchant et al., 2003) during fetal life. Studies in 
mice show that the protective role of  T cells in early life 
is not dependent on  T cells (Ramsburg et al., 2003). 
Conversely, in a model of West Nile virus infection, it has 
been shown that  T cells facilitate the CD8  T cell re-
sponse (Wang et al., 2006). In comparison with adult DC, 
fetal  DC  shows  impaired  functions  (Goriely  et  al.,  2004; 
Levy, 2007). Because  T cell differentiation is not depen-
dent or is less dependent on DC in comparison with   
T cells, it is reasonable to believe that fetal DC defects would 
not prevent  T cell differentiation upon fetal exposure to 
CMV. Instead,  T cells may recognize their ligands directly 
on infected cells in tissues (Hayday, 2009). Such activated   
fetal  T cells could, in turn, induce fetal DC maturation 
(Ismaili et al., 2002; Conti et al., 2005; Caccamo et al., 2006; 
Devilder et al., 2006; Eberl et al., 2009) and/or directly   
activate naive CD8  T cells via antigen cross-presentation 
(Brandes et al., 2009), as shown in adult cells. Such mech-
anisms could contribute to the development of functional 
CD8  T cell responses to CMV infection during fetal life 
(Marchant et al., 2003).
We conclude that human  T cells can mount a vigor-
ous response to CMV infection during development in utero, 
providing an important mechanism by which the fetus can 
fight pathogens. Identification of the  TCR ligands in-
duced upon CMV infection, like the putative ligand of the 
public V8V1 TCR, will likely be useful to design novel 
vaccination strategies against viral infection in early life.
MATERIALS AND METHODS
Study population. This study was approved by the Hôpital Erasme and 
Hôpital Saint-Pierre ethical committees. Women with suspected primary 
CMV infection were referred to the Fetal Medicine Units of the Hôpital 
Erasme or Hôpital Saint-Pierre. Diagnosis of primary maternal infection was 
based on anti-CMV IgG seroconversion or on the detection of high titers of 
anti-CMV–specific IgM, as described previously (Liesnard et al., 2000). 
After maternal informed consent, 20–50 ml of cord blood was collected at 
birth (full term, >37 wk gestation). In some cases, fetal cord blood was   
collected at earlier gestation ages (1 ml by cordocentesis). Diagnosis of 
congenital infection was based on the detection of CMV genome by PCR 
and/or by viral culture on amniotic fluid and/or on newborn urine collected 
during  the  first  week  of  life.  The  study  included  19  CMV-infected   JEM VOL. 207, April 12, 2010 
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30,000 cells/well and, after 6 h, supernatant was collected. Release of IFN- 
into the supernatant was quantified by ELISA (Invitrogen). The killing assay 
was performed as described previously (Vermijlen et al., 2002) with some 
modifications. Fibroblasts with [methyl-3H]thymidine-labeled DNA were 
infected with CMV for 5 d and coincubated with  T cells at the indicated 
effector to target ratios. After 4 h of coincubation, the level of DNA frag-
mentation induced by the  T cells in the fibroblasts was determined as 
previously described (Vermijlen et al., 2002).
CMV replication assay. Confluent monolayers of human embryonic lung 
fibroblasts  (HEL299)  in  flat-bottom  96-well  plates  were  incubated  with 
CMV (TB40/E) for 2 h (MOI 0.1), washed, and incubated with medium 
alone, with a public V8V1 clone or with a control V9V2 clone (150,000 
cells per well). After 7 d, the quantity of infectious CMV from the superna-
tant was determined in quadruplicate by standard plaque assay titration   
(in plaque forming units).
Statistical analysis. Differences between CMV-infected newborns and 
CMV-uninfected newborns were determined using the nonparametric 
Mann-Whitney test using InStat software (GraphPad Software, Inc.). Differ-
ences were regarded as significant at P < 0.05.
Online supplemental material. Fig. S1 shows the V chain expression 
of CMV-infected and CMV-uninfected newborns. Fig. S2 shows the as-
sociation of the late differentiation phenotype of  T cells with the expres-
sion of cytotoxic mediators and chemokine receptor CX3CR1. Fig. S3 shows 
the CDR32 repertoire. Fig. S4 shows TCR/CD3-dependent IFN-  
production  by  more  public  V8V1  clones  upon  coincubation  with 
CMV-infected target cells. Table S1 provides an overview of differen-
tially expressed genes in  T cells from CMV-infected newborns versus 
CMV-uninfected newborns. Tables S2–S4 contain the sequencing data for 
CDR31, CDR32, and CDR38 of CMV-infected and CMV-uninfected 
newborns. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20090348/DC1.
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